Member Info for Doc.Daneeka

What a stroke of luck MrC - your hols will be over before the big day !!

I'd like for you to be right Bob - but I don't think there's anything happening behind the scenes with Barda or NIH.

The results RNS would have been hugely dishonest if this were the case.

I don't have anything really - apart the hope that Starmer surprises me and becomes a great PM and that Southgate's forced changes make us decent at last - and that Emma Raducanu continues her amazing run at Wimbledon. But we can't spend the weekend looking at Tommo's " we get ill - we die" post - much as I approved of it.

Any other reasons to be cheerful ?

Convention has it that when you are cutting and pasting entire posts - you provide the link to the study or abstract - to avoid accusations of plagiarism and/or false erudition

https://www.tandfonline.com/doi/abs/10.1080/14728214.2020.1819982

Brand there will be plenty of drugs trialing for COPD, now and into the future. It's a $26B market after all. For the moment SNG will not be one of them,

RM did not just mention mechanical ventilation in his Proactive interview on June 27th

" This would be things like influenza infections, RSVs , rhinovirus and of course more recently Sars Cov2 infections "

to be fair to him - although he mentioned the COPD data a year ago in the 2022 results interview, he's never said they WOULD trial for Copd. That was just the mugs on here spinning it up. And he hasn't said they'd trial in it because the emerging new drugs don't just give exacerbation relief, but give long term protection. COPD is a maintenance condition rather than something you can actually recover from. SNG doesn't work like this, or at least if it does, it's another possible avenue that Synairgen has no real data for. When RM mentions COPD he talks about the viral clearance signals - nothing more.

There's an interesting switch in tone between the 2022 results interview a year ago - in which he was saying " the data has enabled us to map out a route to develop this drug ...we're targeting high risk patients now.... in trials that will start later this year" and then goes on bullishly to mention platform trials.

https://www.youtube.com/watch?v=QUDQzHyORbY

and the interim interview from 9 months ago in which he said they hadn't identified the cohort and then spent half the time saying they must be careful to rush into the wrong trial. Just a few months between the interviews but they'd already cooled on the ambitious earlier interview and the AGM q&a

https://www.youtube.com/watch?v=Y3gJ9cP7fC8

Hi Aether. We'll know how much hope remains when we hear the details of the ventilated patients trial and how they'll fund it. A

Ensifentrine approved in the US and now EMA signs off on Dupixent. This is why Synairgen made ne mention of COPD in the RNS and why RM didn't include it in his interview, after flagging it up relentlessly for 2 years. The door closes.

" After more than a decade with no treatment advances for chronic obstructive pulmonary disease (COPD), two have been approved by regulators on either side of the Atlantic within a week.

Wednesday, the European Medicines Agency (EMA) signed off on Regeneron and Sanofi’s anti-inflammatory blockbuster Dupixent to treat COPD, which restricts airflow from the lungs and leaves patients struggling to breathe.

This comes seven days after Verona Pharma earned a long-awaited nod from the FDA for Ohtuvayre, ( ensifentrine) a dual inhibitor of the phosphodiesterase 3 (PDE3) and phosphodiesterase 4 (PDE4)

Duxpixent was shown in the BOREAS and NOTUS trials to reduce moderate or severe exacerbations over 52 weeks of treatment by 30% and 34% respectively, compared to placebo. Those results compare to a 40% reduction in flare-ups in Verona’s two trials of after 24 weeks of treatment with Ohtuvayre (Ensifentrine.) "

https://www.fiercepharma.com/pharma/sanofi-and-regenerons-dupixent-scores-europe-first-biologic-treat-copd

Where's scinv, Where'sMrc, Where'sJosh, Are the phones working. ?

Really perplexed by this Tommy. Every morning you call out one of your "trolls " It's almost as if you can't function without starting a punch up. Is it meant to be ironic ? Or have you run out of material ?

Decided I needed to stay active specifically to counter your shameless continued ramping Tommy. You were wrong on everything and yet turned up for work the very next day still spewing your ridiculous guff. Take a few days off and see how much I post. See if you can do it. You are fake.

Welcome back Fruits. You had me worried for a moment there. Pmjh handled the bird flu pandemic in your absence. Moderna making a human mRNA vaccine for the States which will, im sure, reassure you - although Covid on the rise again, which will cause you some concern. Just heard of the first couple of cases with friends and hoping it doesn't run amock in schools before they break up.

England are still somehow in the Euros, Cav has won his record breaking 35th Tour etape, Biden has had a very senior moment, and tomorrow we will see the last rites performed over the Conservative Party.

There -that's you up to date. What's been happening in Little Wallop ?

Good luck Bob. That'll help the exit you need anyway

" Shares in Finnish biotech Faron Pharma are in free fall this morning after a late-stage trial of its lead drug Traumakine for acute respiratory distress syndrome (ARDS) comprehensively failed.

The result took the company and investors by surprise, coming just a few weeks after Faron had been trumpeting its preparations for regulatory filings for Traumakine in Europe and the U.S. at its R&D day in London, including a ramp-up in manufacturing capacity.

The company’s shares on the London Stock Exchange were down 83% after the announcement "

May 8th 2018 Fierce Pharma

Traumakine is injected of course and we know there's good evidence that inhalation is a more efficient delivery method - but doesn't all of this sound scarily familiar. Faron not a one trick pony though so still in business with a cancer candidate but the sp dropped from £7.22 to 50p after this failure - and has now partially recovered to 94p following a £30m placing.

Pretty sure the poster meant purdah for the UK election.

Thanks Tom - another brilliant link. But you need to re-read the RNS. It wasn't a placeholding statement while they get their ducks in a row and continue the big plan. It was a capitulation. Financial and scientific capitulation and surrender. An admission that the SNG (with Synairgen) story is mostly over, and that if it wasn't, they don't have the cash to explore the last remaining tiny hope of salvation.

Keep up the good work though and please send anything you find to PO Box 25. Beckenham. Kent. BR3 4BR. Michelle will print it off and make paper airplanes

My thoughts on the delay Bob is that

As someone else suggested - they are close to being ready with an update on the Ventilated patient trial (on the verge) and maybe wanted to get it out with the results and B4 the AGM. It doesn't explain the missed AGM deadline but I can't think of anything else positive that might explain it. I'm disinclined to believe any of the tea leaf readers who have never once been right in any of their secret squirrel predictions. We know that when it looks like nothing is happening with this company - there really is nothing going on.

Appreciate your posts always of course

Hahaha !

"The recent BARDA announcement re. the PT for ARDS was released 24 June and SNG AR & Update followed on 27 June…very close timing. “An additional company and product may be added to the clinical trial at a later time. “ I do expect this to be SNG and that the hold up is due to the PU.RDAH caused by the unexpected election and that NHIR are planning a financed collaboration with SNG and BARDA Thanks again Brand. "

We all feel the same pain Bob, but Scotsmen are normally praised for their hardnosed cannyness, and if you really believe this you must have been dropped on your head as a baby. Raking through the ashes for comfort is one thing but the idea that Barda & NIH have been planning a big swoop for SNG - which is now on hold because of the election is just comical. And if it was somehow true then the results RNS was a really big lie.

We are waiting to hear more - to find out how far along the road they are with the ventilated patients trial - which SS told us they were "on the verge" of announcing. And we wait to hear how they hope to finance it. That's all there is.

You could spend all day discussing this - or read Jonnyboy's reply.

" Funny enough I was looking at this. I see a trend of the accounts being posted near or around July 6th. So let’s see "

Apologies to Vilobelimab - 368 is a decent trial size and proper P2/3.

https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(22)00297-1/fulltext

Clearly SNG is nowhere near being a candidate for this. Miles off, but if you really want to guess the protocols and endpoints, lemme see if I can help

Inclusion criteria. Ventilated with ARDS. Primary endpoints...er........ Mortality ? Secondary... er.... more mortality & discharge from hospital.

Both drugs have already published small P2s for ARDS and they're probably 2-3 years ahead of SNG in this field ( clinical trials are difficult and take time - as we've all been reminded many times ) assuming someone comes up with the proof of concept stake money - and the eventual P2 data is close enough to these results.

Paridiprubart

Mortality at 28-days post-treatment was 7.7% (1/13) in the paridiprubart group versus 40.0% (8/20) for placebo (OR=0.125; 95% CI, 0.013-1.160; P=0.067; P[bootstrap]=0.011). 60-day mortality was 23.1% (3/13) in paridiprubart-treated patients and 45.0% (9/20) in placebo patients (OR=0.367; 95% CI, 0.077-1.749; P=0.208; P[bootstrap]=0.162). Mean survival time was 55.78 days for paridiprubart recipients compared to 41.44 days for placebo patients (HR=0.386; 95% CI, 0.077-1.436; P=0.156; P[bootstrap]=0.083).

Conclusions: In COVID-19 patients with ARDS requiring invasive ventilation and organ support,

paridiprubart was efficacious in preventing mortality and improving clinical outcomes, with no

safety concerns.

Vilobelimab

54 patients (31%) of 177 in the vilobelimab group and 77 patients (40%) of 191 in the placebo group died in the first 28 days. The all-cause mortality rate at 28 days was 32% (95% CI 25–39) in the vilobelimab group and 42% (35–49) in the placebo group (hazard ratio 0·73, 95% CI 0·50–1·06; p=0·094). In the predefined analysis without site-stratification, vilobelimab significantly reduced all-cause mortality at 28 days (HR 0·67, 95% CI 0·48–0·96; p=0·027). 

Conclusions: In addition to standard of care, vilobelimab improves survival of invasive mechanically ventilated patients with COVID-19 and leads to a significant decrease in mortality. Vilobelimab could be considered as an additional therapy for patients in this setting